A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

PMID- 28859431
DA  - 20170901
DCOM- 20170907
LR  - 20170907
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 216
IP  - 3
DP  - 2017 Aug 01
TI  - Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling
PG  - 336-344
LID - 10.1093/infdis/jix299 [doi]
AB  - Background: Human papillomavirus (HPV) vaccination is still not reaching many
      high-risk populations. HPV16/18 vaccines offer cross-protection against other
      types, for example, HPV45. Both direct vaccine efficacy and indirect herd
      protection contribute to vaccination effectiveness. Methods: We used a dynamic
      transmission model, calibrated to cervical screening data from Italy, to estimate
      vaccination effectiveness against HPV16 and HPV45 infection, assuming for HPV45
      either 95% or lower cross-protection. Results: Basic reproductive number was
      smaller (2.1 vs 4.0) and hence vaccine effectiveness and herd protection stronger
      for HPV45 than for HPV16. The largest difference in the reduction of infection
      prevalence in women <35 years old was found at 70% coverage in girls-only
      vaccination programs (99% vs 83% for total protection for HPV45 and HPV16,
      respectively, mainly owing to stronger herd protection, ie, 37% vs 16%). In
      gender-neutral vaccination, the largest difference was at 40% coverage (herd
      protection, 54% vs 28% for HPV16 and HPV45, respectively). With >/=80% coverage, 
      even 50% cross-protection would reduce HPV45 by >/=94%. Conclusions: The
      characteristics of individual high-risk HPV types strongly influence herd
      protection and determine the level of coverage and cross-protection required to
      reduce or eliminate the infection through HPV vaccination. HPV16 infection and
      related cancers are the most difficult to eliminate.
FAU - Baussano, Iacopo
AU  - Baussano I
AD  - International Agency for Research on Cancer, Lyon, France.
FAU - Lazzarato, Fulvio
AU  - Lazzarato F
AD  - International Agency for Research on Cancer, Lyon, France.
AD  - Unit of Cancer Epidemiology, AOU Citta della Salute e della Scienza, Hospital of 
FAU - Ronco, Guglielmo
AU  - Ronco G
AD  - Department of Cancer Screening, Centre for Epidemiology and Prevention in
      Oncology, Turin, Italy.
FAU - Lehtinen, Matti
AU  - Lehtinen M
AD  - University of Tampere, Finland.
AD  - Department of Laboratory Medicine, Karolinska Institute, Huddinge, Sweden.
FAU - Dillner, Joakim
AU  - Dillner J
AD  - Department of Laboratory Medicine, Karolinska Institute, Huddinge, Sweden.
FAU - Franceschi, Silvia
AU  - Franceschi S
AD  - International Agency for Research on Cancer, Lyon, France.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Papillomavirus Vaccines)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Child
MH  - Cross Protection/immunology
MH  - Female
MH  - *Human papillomavirus 16
MH  - *Human papillomavirus 18
MH  - Humans
MH  - Immunity, Herd/immunology
MH  - Immunization Programs
MH  - Italy
MH  - Male
MH  - Middle Aged
MH  - Models, Theoretical
MH  - Papillomavirus Infections/*prevention & control
MH  - Papillomavirus Vaccines/*administration & dosage
MH  - Uterine Cervical Neoplasms/*prevention & control/virology
MH  - Young Adult
OT  - HPV vaccination
OT  - cervical cancer control
OT  - cross-protection
OT  - herd effect
EDAT- 2017/09/02 06:00
MHDA- 2017/09/08 06:00
CRDT- 2017/09/02 06:00
PHST- 2017/04/11 [received]
PHST- 2017/06/30 [accepted]
AID - 3925344 [pii]
AID - 10.1093/infdis/jix299 [doi]
PST - ppublish
SO  - J Infect Dis. 2017 Aug 1;216(3):336-344. doi: 10.1093/infdis/jix299.